Risk of Recurrence by Nodal Status and High-Risk Features in Patients with HR+, HER2-, Early Breast Cancer: An Analysis of Real-world Data

被引：0
|
作者：
Grimes, B. [1 ]
Tolaney, S. M. [2 ]
Sammons, S. [2 ]
Cortes, J. [3 ,4 ]
Liepa, A. M. [1 ]
Sugihara, T. [5 ]
Cui, Z. Lin [1 ]
Gathirua-Mwangi, W. [1 ]
Shahir, A. [1 ]
Monaco, M. [1 ]
Neven, P. [6 ]
Johnston, S. [7 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[3] Quironsalud Grp, Inst Int Breast Canc Ctr, Dept Med, Pangaea Oncol, Barcelona, Spain
[4] Univ Europea Madrid, Fac Biomed & Hlth Sci, Madrid, Spain
[5] Syneos Hlth, Morrisville, NC USA
[6] Univ Hosp Leuven, Louvain, Belgium
[7] Royal Marsden NHS Fdn Trust, London, England
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.103897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P003
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-World Observational Study of Incidence and Outcomes in an HR+/HER2- Early Breast Cancer Population with High-Risk of Recurrence in Finland
    Singh, Ravinder
    Tuominen, Samuli
    Lassenius, Mariann I.
    Auvinen, Merja
    Torstensson, Astrid
    Wiklund, Tom
    ONCOLOGY AND THERAPY, 2025, 13 (01) : 185 - 200
  • [2] Real-world study on HR+, HER2-, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns
    Pivot, X.
    Chartier, F.
    Chouaki, N.
    Brown, J.
    Williams, R.
    Rider, A.
    BREAST, 2021, 56 : S37 - S38
  • [3] Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2- Breast Cancer
    Valerio, Maria Rosaria
    Martorana, Federica
    Sano, Maria Vita
    Sambataro, Daniela
    Motta, Gianmarco
    Motta, Lucia
    Pavone, Giuliana
    Gebbia, Vittorio
    Scandurra, Giuseppa
    BIOMEDICINES, 2025, 13 (03)
  • [4] Costs of breast cancer recurrence after initial treatment for HR+, HER2-, high-risk early breast cancer: estimates from SEER-Medicare linked data
    Vitko, Alexandra S.
    Martin, Pam
    Zhang, Sheng
    Johnston, Adam
    Ohsfeldt, Robert
    Zheng, Shen
    Liepa, Astra M.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 84 - 96
  • [5] Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
    Christiansen, Emilie Adrian
    Kuemler, Iben
    FUTURE SCIENCE OA, 2024, 10 (01):
  • [6] Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2-early breast cancer
    O'Shaughnessy, Joyce
    Tolaney, Sara M.
    Yardley, Denise A.
    Hart, Lowell
    Razavi, Pedram
    Fasching, Peter A.
    Janni, Wolfgang
    Schwartzberg, Lee
    Kim, Julia
    Akdere, Murat
    McDermott, Courtney
    Khakwani, Aamir
    Pathak, Purnima
    Graff, Stephanie L.
    BREAST, 2025, 81
  • [7] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Masakazu
    Martin, Miguel
    Shao, Zhi Min
    Zhang, Qing Yuan
    Martinez Rodriguez, Jorge Luis
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Okada, Morihito
    Boyle, Frances
    Neven, Patrick
    Cortes, Javier
    Huober, Jens
    Wardley, Andrew
    Tolaney, Sara M.
    Cicin, Irfan
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    San Antonio, Belen
    Hulstijn, Maarten
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
  • [8] Identification of Patients with Early HR+HER2-Breast Cancer at High Risk of Recurrence
    Fasching, Peter A.
    Kreipe, Hans
    Del Mastro, Lucia
    Ciruelos, Eva
    Freye, Gilles
    Korfe, Agnieszka
    Chouaki, Nadia
    Stoffregen, Clemens
    Sapunar, Francisco
    Camero, David
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (02) : 164 - 184
  • [9] Clinicopathological features of HR+/HER2 low breast cancer in a real-world setting in China
    Min, Z.
    Zhou, F.
    Qu, H.
    Ren, Y.
    Liang, W.
    Liu, M.
    Wang, J.
    Luo, J.
    Tan, X.
    Dai, G.
    Hu, G.
    Meng, Q.
    He, W.
    Wang, H.
    Liu, W.
    Tang, H.
    Wu, Q.
    Liu, H.
    Tian, Y.
    Qin, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S1412 - S1412
  • [10] Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
    Turner, Nicholas
    Reis-Filho, Jorge
    Goetz, Matthew
    Desmedt, Christine
    Chandarlapaty, Sarat
    Sasano, Hironobu
    Arteaga, Carlos
    Loi, Sherene
    Graff, Stephanie
    Liu, Deli
    Rodrik-Outmezguine, Vanessa
    Sireci, Anthony
    Rubenstein, Cynthia Sandoval
    Won, Helen
    Litchfield, Lacey M.
    Munoz, Maria
    Johnston, Stephen
    CANCER RESEARCH, 2024, 84 (09)
12345